Financial Performance - The total revenue for the year ended March 31, 2025, was HKD 94,448,000, an increase of 15.3% compared to HKD 81,903,000 for the year ended March 31, 2024[6] - Gross profit for the year was HKD 45,722,000, representing a gross margin of approximately 48.4%[6] - The net profit for the year was HKD 9,191,000, up 18.1% from HKD 7,790,000 in the previous year[6] - Basic earnings per share increased to HKD 1.18 from HKD 0.98, reflecting a growth of 20.4%[6] - The group generated revenue of HKD 94,292,000 in 2025, an increase from HKD 81,747,000 in 2024, representing a growth of approximately 15.5%[22] - The pre-tax profit before income tax reached HKD 9,460,000 in 2025, an increase from HKD 7,855,000 in 2024, representing a growth of approximately 20.4%[30] - The group reported a net profit of approximately HKD 9,200,000 for the fiscal year ending March 31, 2025, an increase of about HKD 1,400,000 from HKD 7,800,000 in the previous year[50] Revenue Breakdown - Revenue from medical equipment sales reached HKD 31,657,000 in 2025, significantly up from HKD 22,899,000 in 2024, marking an increase of about 38.3%[22] - The total revenue from medical consumables was HKD 58,646,000 in 2025, up from HKD 54,985,000 in 2024, indicating an increase of approximately 4.8%[22] - The group reported a total of HKD 2,317,000 in revenue from maintenance services in 2025, compared to HKD 2,107,000 in 2024, reflecting a growth of approximately 10%[22] - Major customer A contributed HKD 18,608,000 to total revenue in 2025, while customer B contributed HKD 9,743,000, down from HKD 10,453,000 in 2024[21] Expenses and Costs - Selling and distribution expenses rose to HKD 1,397,000 from HKD 1,319,000, indicating a 5.9% increase[6] - Administrative and other operating expenses increased to HKD 37,785,000 from HKD 35,354,000, a rise of 6.9%[6] - Research and development expenses were HKD 3,926,000 in 2025, slightly down from HKD 4,080,000 in 2024, showing a decrease of about 3.8%[26] - The total employee costs, including directors' remuneration, amounted to HKD 24,031,000 in 2025, up from HKD 21,165,000 in 2024, representing an increase of about 13.5%[26] Assets and Liabilities - Total assets increased to HKD 121,640,000 from HKD 104,195,000, representing a growth of approximately 16.7% year-over-year[7] - Current assets rose to HKD 60,235,000 compared to HKD 59,988,000, indicating a slight increase of 2.1%[7] - Total liabilities increased to HKD 18,695,000 from HKD 11,219,000, reflecting a significant rise of approximately 66.5%[7] - Net current assets improved to HKD 102,945,000 from HKD 92,976,000, marking an increase of about 10.6%[7] - Equity attributable to owners of the company rose to HKD 110,786,000 from HKD 103,326,000, a growth of approximately 7.4%[7] Financial Reporting Standards - The revised Hong Kong Financial Reporting Standards will take effect on April 1, 2024, with no significant impact on the group's consolidated financial statements[13] - The group intends to adopt new and revised Hong Kong Financial Reporting Standards upon their effective date, which are expected to have no major impact on the group's performance and financial position[16] - The group is currently analyzing the new regulations and assessing the impact of Hong Kong Financial Reporting Standard No. 18 on its consolidated financial statements[17] - The group expects that the adoption of the revised standards will not have a significant impact on its consolidated financial statements[16] Corporate Governance - The group has adopted the GEM Listing Rules and has complied with all governance code provisions except for C.2.1, which states that the roles of the chairman and CEO should be separated[70] - The board believes in its independence and effectiveness, supported by a diverse background and expertise of its directors, along with established independent checks and balances[71] - The audit committee consists of two independent non-executive directors and one non-executive director, ensuring compliance with GEM Listing Rules[81] - The group's financial performance for the year ending March 31, 2025, has been reviewed by the audit committee[81] Future Outlook - The company plans to continue expanding its market presence and developing new products in the upcoming fiscal year[5] - Future guidance indicates a focus on improving operational efficiency and enhancing shareholder value[5] - The group is optimistic about the healthcare sector due to the increasing elderly population and rising health awareness among Hong Kong citizens[44] Miscellaneous - The company declared an interim dividend of HKD 2,000,000 for 2025, consistent with the HKD 2,000,000 declared in 2024[29] - The company has no outstanding contributions to defined contribution retirement plans as of March 31, 2025, which is consistent with the previous year[26] - The company has not engaged in any buybacks or sales of its listed securities during the year[68] - The company made a donation of approximately HKD 900,000 during the year[79]
君百延集团(08372) - 2025 - 年度业绩